15 Advanced Solid Tumors Clinical Trials in Orange, NJ (2026)

Q: How do I join a clinical trial in Orange?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Orange research site will contact you.

Recruiting Advanced Solid Tumors Studies in Orange

NCT03486873Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this ex...

Orange, NJ3,500 participantsMerck Sharp & Dohme LLC

View Study Details

NCT03093116Recruiting

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotre...

Orange, NJ500 participantsTurning Point Therapeutics, Inc.

View Study Details

NCT05410145Recruiting

A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prel...

Orange, NJ442 participantsD3 Bio (Wuxi) Co., Ltd

View Study Details

NCT04900818Recruiting

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors....

Orange, NJ330 participantsI-Mab Biopharma US Limited

View Study Details

NCT07160725Recruiting

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors...

Orange, NJ315 participantsBristol-Myers Squibb

View Study Details

NCT06219941Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participant...

Orange, NJ224 participantsAstraZeneca

View Study Details

NCT07396584Recruiting

HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor

This is a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors....

Orange, NJ186 participantsHutchmed

View Study Details

NCT07436728Recruiting

A Study of TAK-505 in Adults With Solid Tumors

Solid tumors occur when cells in an organ or tissue (for example in the lung or liver) start growing out of control (cancer) and form a lump or mass of cells. These solid cancers may grow very far in ...

Orange, NJ151 participantsTakeda

View Study Details

NCT04851119Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to tr...

Orange, NJ147 participantsChildren's Oncology Group

View Study Details

NCT06620302Recruiting

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors a...

Orange, NJ81 participantsChildren's Oncology Group

View Study Details

NCT05038150Recruiting

Study of SGN1 in Patients With Advanced Solid Tumor

Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Ration...

Orange, NJ70 participantsGuangzhou Sinogen Pharmaceutical Co., Ltd

View Study Details

NCT04870944Recruiting

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has c...

Orange, NJ63 participantsChildren's Oncology Group

View Study Details

NCT06444815Recruiting

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET...

Orange, NJ60 participantsKaliVir Immunotherapeutics

View Study Details

NCT06824363Recruiting

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

This is a proof of principle clinical trial determining efficacy of single dose dualimmune checkpoint inhibitors to increase intra-tumoral T cells in esophageal, gastroesophageal junction, and gastric...

Orange, NJ34 participantsUniversity of California, Irvine

View Study Details

NCT02446431Recruiting

Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence

Most pediatric patients with solid tumors respond to initial high-dose, intensive therapy and complete treatment in remission. High-risk patients however, frequently have recurrent disease which is th...

Orange, NJ20 participantsMiller Children's & Women's Hospital Long Beach

View Study Details

About Advanced Solid Tumors Clinical Trials in Orange

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 15 advanced solid tumors clinical trials recruiting participants in Orange, NJ. These studies are seeking a combined 6,123 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Turning Point Therapeutics, Inc., D3 Bio (Wuxi) Co., Ltd and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Orange — FAQ

Are there advanced solid tumors clinical trials in Orange?

Yes, there are 15 advanced solid tumors clinical trials currently recruiting in Orange, NJ. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Orange?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Orange research site will contact you about next steps.

Are clinical trials in Orange free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Orange studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 15 active trials in Orange are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 13, 2026 from ClinicalTrials.gov